The Lancet Rheumatology

The Lancet Rheumatology is a monthly online journal launched in 2019 by The Lancet Group and published by Elsevier, covering the diagnosis, classification, management and prevention of rheumatic diseases, with a 2025 Journal Impact Factor of 29.5《柳叶刀：风湿病学》由柳叶刀集团于 2019 年创办、由爱思唯尔（Elsevier）出版，是月刊在线期刊，涵盖风湿性疾病的诊断、分类、管理与预防，2025 年影响因子为 29.5。

Scope

• It publishes clinical research with a focus on clinical trials, together with expert reviews and provocative comment and opinion该刊刊载以临床试验为重点的临床研究，以及专家综述与富有启发性的评论与观点。^[1]
• Its content relates to the diagnosis and classification, management and prevention of rheumatic diseases, including arthritic, musculoskeletal and connective tissue diseases as well as disorders of the immune system其内容涉及风湿性疾病的诊断与分类、管理与预防，包括关节性、肌肉骨骼与结缔组织疾病以及免疫系统疾病。
• It also publishes high-quality human translational studies supported by robust clinical data该刊还刊载有可靠临床数据支撑的高质量人体转化研究。
• Priority is given to studies that identify potential new therapeutic targets and advance efforts toward precision medicine优先考虑能发现潜在新治疗靶点、推动精准医学发展的研究。
• It is committed to publishing content relevant to rheumatology specialists worldwide, focusing on studies that advance clinical practice, challenge the status quo and advocate change in health policy该刊致力于发表与全球风湿病学专家相关的内容，聚焦那些推进临床实践、挑战现状、倡导卫生政策变革的研究。
• It is published online only with no print edition, and as a hybrid journal some articles are published open access该刊仅在线出版、没有印刷版，作为混合型期刊，部分文章以开放获取出版。

History

• The journal was launched in summer 2019 by The Lancet Group as a new specialty title该刊由柳叶刀集团于 2019 年夏季创办，是新增的专科期刊。
• It was established under Heather Van Epps, PhD, as founding Editor-in-Chief该刊由 Heather Van Epps（博士）以创始主编身份主持创办。
• It extended the Lancet specialty portfolio, which had earlier expanded into diabetes and endocrinology, gastroenterology and hepatology and other fields该刊拓展了柳叶刀专科期刊组合，此前该组合已延伸至糖尿病与内分泌学、胃肠病学与肝病学等领域。
• It has been published online only since launch, reflecting the group's digital-first approach for several specialty titles该刊自创刊起即仅在线出版，体现该集团对多个专科刊的数字化优先策略。
• Its 2025 Journal Impact Factor is 29.5, up from 16.4 in 2024, placing it among the leading rheumatology journals其 2025 年影响因子为 29.5，高于 2024 年的 16.4，位居风湿病学期刊前列。
• In the Journal Citation Reports it ranks second among 58 rheumatology journals在（Journal Citation Reports）中，该刊在 58 种风湿病学期刊里位列第二。

Editors

• The Editor-in-Chief is Heather Van Epps, PhD现任主编为 Heather Van Epps（博士）。
• She received a PhD in immunology from UMass Chan Medical School, studying T lymphocyte biology and function during viral infection她在（UMass Chan Medical School）取得免疫学博士学位，研究病毒感染中的 T 淋巴细胞生物学与功能。
• After a postdoctoral fellowship at Memorial Sloan Kettering Cancer Center, she served as an Editor at The Journal of Experimental Medicine在（Memorial Sloan Kettering Cancer Center）完成博士后研究后，她曾任（The Journal of Experimental Medicine）编辑。
• She joined the Lancet group in 2015 and acted as Deputy Editor for The Lancet Diabetes and Endocrinology and The Lancet Gastroenterology and Hepatology她 2015 年加入柳叶刀团队，曾任（The Lancet Diabetes and Endocrinology）与（The Lancet Gastroenterology and Hepatology）的副编辑。
• She launched The Lancet Rheumatology as founding Editor-in-Chief in 2019 and co-chairs the Lancet Gender and Diversity Taskforce她于 2019 年以创始主编身份创办《柳叶刀：风湿病学》，并共同主持柳叶刀性别与多样性工作组。